Moderna's COVID-19 vaccine has efficacy edge over Pfizer shot, study finds

By HealthDay News
Moderna's COVID-19 vaccine has efficacy edge over Pfizer shot, study finds
While both two-dose vaccines against COVID-19 available United States are effective, new research shows the Moderna vaccine is more effective than the one from Pfizer-BioNTech. File Photo by Keizo Mori/UPI | License Photo

Which coronavirus vaccine is best at beating COVID-19 -- Moderna or Pfizer?

New research hands that honor to Moderna: In what is billed as the first head-to-head comparison of the two shots, researchers analyzed the health records of nearly 440,000 U.S. veterans who received one of the two vaccines between early January 2021 and mid-May 2021.


All were followed for 24 weeks.

While both vaccines were highly effective in preventing infection, hospitalization and death, the Moderna vaccine conferred a 21% lower risk of infection and a 41% lower risk of hospitalization.

RELATED Omicron is here; how fast it will spread remains unclear, experts say

"Both vaccines are incredibly effective, with only rare breakthrough cases," said research team member Dr. J.P. Casas, an epidemiologist and associate professor with Brigham and Women's Hospital and Harvard Medical School.

He is also executive director of the U.S. Department of Veterans Affairs Million Veteran Program for genetics and health research.

"But regardless of the predominant strain -- Alpha earlier and then Delta later -- Moderna was shown to be slightly more effective," Casas noted in a VA news release.

RELATED COVID-19 vaccines less effective in cancer patients receiving chemotherapy

The infection rate during the follow-up period was 4.52 per 1,000 in the Moderna vaccine group and 5.75 per 1,000 in the Pfizer group.


Those in the Pfizer group also had higher rates of symptomatic COVID-19 (0.44 more per 1,000), hospitalization (0.55 more per 1,000), ICU admission (0.10 more per 1,000), and death (0.02 more per 1,000) than those in the Moderna group.

An additional phase of the study covering the period when Delta was the main strain in the United States showed that the risk of infection was still higher among those in the Pfizer group (6.54 more per 1,000) than in the Moderna group.

RELATED British expert: Omicron variant unlikely to seriously affect the vaccinated

The findings were published Wednesday in the New England Journal of Medicine.

"Given the high effectiveness of both the Moderna and Pfizer vaccines, confirmed by our study, either one is recommended to any individual offered a choice between the two," said study first author Barbra Dickerman, an epidemiology instructor at the Harvard T.H. Chan School of Public Health.

"However, while the estimated differences in effectiveness were small on an absolute scale, they may be meaningful when considering the large population scale at which these vaccines are deployed. This information may be helpful for larger decision-making bodies," Dickerman said in the release.

Further evaluation of the two vaccines' effectiveness and safety is needed, but given "the high effectiveness and safety profile of both mRNA vaccines, either one is strongly recommended," the researchers concluded.


Previous randomized trials found that the Pfizer vaccine was 95% effective and the Moderna vaccine 94% effective against symptomatic COVID-19 infection, and similar levels of protection were found in real-world use.

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccines.

Copyright © 2021 HealthDay. All rights reserved.

Latest Headlines


Follow Us